Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

RO-7589831

Alternative Names: RO-7589831, RO 7589831, RO7589831
Latest Update: 2025-03-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: WRN Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RO-7589831

Countries in Clinic: Belgium, Canada, Denmark, France, Spain, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
dMMR

P1

Recruiting

Oncology Solid Tumor Unspecified

2027-05-31

Recent News Events

Date

Type

Title

04/25/2024

News Article

 Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions